Core Viewpoint - ALK reported a strong Q2 performance with a 12% organic revenue growth and a 41% increase in operating profit, leading to an upgraded full-year revenue outlook [1][6]. Q2 Performance Highlights - Revenue for Q2 2025 reached DKK 1,527 million, reflecting a 12% growth in local currency and an 11% growth in reported currency [3]. - Operating profit (EBIT) for Q2 was DKK 375 million, marking a 41% increase in local currency and a 42% increase in reported currency, with an EBIT margin of 25% [3]. - For H1 2025, revenue totaled DKK 3,049 million, with a consistent 12% growth in both local and reported currencies [3]. Financial Highlights - Full-year revenue outlook has been upgraded to a growth expectation of 12-14% in local currencies, previously estimated at 9-13% [6][13]. - Tablet sales grew by 16% to DKK 831 million, with Europe and North America showing significant growth rates of 17% and 32%, respectively [6]. - Sales of Other products and services increased by 30% to DKK 215 million, while anaphylaxis revenue surged by 56% [6]. Strategic Initiatives - The launch of new products, including the house dust mite tablet and the neffy adrenaline nasal spray, has exceeded initial market expectations [7][8]. - A dedicated pediatric sales force in the USA has been fully deployed, contributing to growth initiatives [7][8]. - Patient recruitment for the clinical phase 2 trial with the peanut allergy tablet was completed ahead of schedule [7].